Diện tích lách trước phẫu thuật như một dấu hiệu sinh học dự đoán cho ung thư phổi không tế bào nhỏ giai đoạn sớm

Bade BC, Dela Cruz CS. Lung Cancer 2020: epidemiology, etiology, and Prevention. Clin Chest Med. 2020;41:1–24. Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, et al. A Japanese Lung Cancer Registry Study: prognosis of 13,010 resected Lung Cancers. J Thorac Oncol. 2008;3:46–52. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small cell Lung cancer (NSCLC): ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv1–2. Kelsey CR, Marks LB, Hollis D, Hubbs JL, Ready NE, D’Amico TA, et al. Local recurrence after Surgery for early stage Lung cancer: an 11-year experience with 975 patients. Cancer. 2009;115:5218–27. Fedor D, Johnson WR, Singhal S. Local recurrence following Lung cancer Surgery: incidence, risk factors, and outcomes. Surg Oncol. 2013;22:156–6. Carnio S, Novello S, Papotti M, Loiacono M, Scagliotti GV. Prognostic and predictive biomarkers in early stage non-small cell Lung cancer: Tumor based approaches including gene signatures. Transl Lung Cancer Res. 2013;2:372–8. Prasetyanti PR, Medema JP. Intratumor heterogeneity from a cancer stem cell perspective. Mol Cancer. 2017;16. Ramspek CL, Jager KJ, Dekker FW, Zoccali C, van Diepen M. External validation of prognostic models: what, why, how, when and where? Clin Kidney J. 2020;14:49–58. Thakur MK, Gadgeel SM. Predictive and prognostic biomarkers in Non-small Cell Lung Cancer. Semin Respir Crit Care Med. 2016;37:760–70. Brueckl WM, Ficker JH, Zeitler G. Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell Lung cancer (NSCLC). BMC Cancer. 2020;20:1185. Coate LE, John T, Tsao M-S, Shepherd FA. Molecular predictive and prognostic markers in non-small cell Lung cancer. Lancet Oncol. 2009;10:1001–10. Bai R-L, Chen N-F, Li L-Y, Cui J-W. A brand new era of cancer immunotherapy: breakthroughs and challenges. Chin Med J. 2021;134:1267–75. Marschollek K, Brzecka A, Pokryszko-Dragan A. New biochemical, immune and molecular markers in Lung cancer: diagnostic and prognostic opportunities. Adv Clin Exp Med. 2022;31:1391–41. Chadburn A. The spleen: anatomy and anatomical function. Semin Hematol. 2000;37:13–2. Xiao L-S, Hu C-Y, Cui H, Li R-N, Hong C, Li Q-M, et al. Splenomegaly in predicting the survival of patients with advanced primary Liver cancer treated with immune checkpoint inhibitors. Cancer Med. 2022;11:4880–8. Suzuki R, Ishii S, Watanabe H, Takagi T, Sugimoto M, Sato Y et al. Splenic volume as a prognostic indicator for unresectable Pancreatic cancer. World Acad Sci J. 2020;3. Bae JS, Lee DH, Yoo J, Yi N-J, Lee K-W, Suh K-S, et al. Association between spleen volume and the posthepatectomy Liver Failure and overall survival of patients with hepatocellular carcinoma after resection. Eur Radiol. 2021;31:2461–7. Galland L, Lecuelle J, Favier L, Fraisse C, Lagrange A, Kaderbhai C, et al. Splenic volume as a surrogate marker of Immune checkpoint inhibitor efficacy in metastatic non-small cell Lung Cancer. Cancers (Basel). 2021;13:3020. Castagnoli F, Doran S, Lunn J, Minchom A, O’Brien M, Popat S, et al. Splenic volume as a predictor of treatment response in patients with non-small cell Lung cancer receiving immunotherapy. PLoS ONE. 2022;17:e0270950. Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13:31–4. Clark K, Vendt B, Smith K, Freymann J, Kirby J, Koppel P, et al. The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository. J Digit Imaging. 2013;26:1045–57. Bakr S, Gevaert O, Echegaray S, Ayers K, Zhou M, Shafiq M, Zheng H, Benson JA, Zhang W, Leung ANC, Kadoch M, Hoang CD, Shrager J, Quon A, Rubin DL, Plevritis SK. S. Napel, Data for NSCLC Radiogenomics Collection, The Cancer Imaging Archive. (2017). 2017.7hs46erv. W HJAL, Wee L, Rios Velazquez E, Leijenaar RTH, Parmar C, Grossmann P, Bussink SCJ, Monshouwer R, Haibe-Kains B, Rietveld D, Hoebers F, Rietbergen MM, Leemans CR, Dekker A, Quackenbush J, Gillies RJ. P.Lambin, (2019). Data from NSCLC-Radiomics (dataset). The Cancer Imaging Archive. 2015.PF0M9REI. Schmoldt A, Benthe HF, Haberland G. Digitoxin metabolism by rat liver microsomes. Biochem Pharmacol. 1975;24(17):1639–164. Aerts HJWL, Velazquez ER, Leijenaar RTH, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:4006. Lusa L, Ahlin Č. Restricted cubic splines for modelling periodic data. PLoS ONE. 2020;15:e0241364. Albayrak E, Server S. The relationship of spleen stiffness value measured by shear wave elastography with age, gender, and spleen size in healthy volunteers. J Med Ultrasonics. 2019;46:195–9. Mitsuyama Y, Shimizu K, Hirayama A, Komukai S, Kitamura T, Ogura H, et al. Splenic volume on computed tomography scans is associated with mortality in patients with sepsis. Int J Infect Dis. 2021;104:624–30. Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5:3–8. Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the Tumor Microenvironment. Trends Immunol. 2016;37:208–20. Li X, Xing Y-F, Lei A-H, Xiao Q, Lin Z-H, Hong Y-F, et al. Neutrophil count is associated with myeloid derived suppressor cell level and presents prognostic value for hepatocellular carcinoma patients. Oncotarget. 2017;8:24380–8. Toor SM, Syed Khaja AS, El Salhat H, Faour I, Kanbar J, Quadri AA, et al. Myeloid cells in circulation and Tumor microenvironment of Breast cancer patients. Cancer Immunol Immunother. 2017;66:753–64. Jordan KR, Kapoor P, Spongberg E, Tobin RP, Gao D, Borges VF, et al. Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients. Cancer Immunol Immunother. 2017;66:503–13. Stewart TJ, Greeneltch KM, Reid JE, Liewehr DJ, Steinberg SM, Liu K, et al. Interferon regulatory factor-8 modulates the development of tumour-induced CD11b + Gr-1 + myeloid cells. J Cell Mol Med. 2009;13:3939–50. Shen P, Wang A, He M, Wang Q, Zheng S. Increased circulating Lin–/lowCD33+HLA-DR–myeloid-derived suppressor cells in hepatocellular carcinoma patients. Hepatol Res. 2013;44:639–50. Cortez-Retamozo V, Etzrodt M, Newton A, Rauch PJ, Chudnovskiy A, Berger C, et al. Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci USA. 2012;109:2491–6. Higashijima J, Shimada M, Chikakiyo M, Miyatani T, Yoshikawa K, Nishioka M, et al. Effect of splenectomy on antitumour immune system in mice. Anticancer Res. 2009;29:385–93. Schranz T, Klaus J, Kratzer W, Schmidberger J, Güthle M. A comparison of spleen size measured by ultrasound in a random population sample and a matched sample of patients at a university hospital, and the determination of normal values and influencing factors. Z Gastroenterol. 2021;59:438–45. Chow KU, Luxembourg B, Seifried E, Bonig H. Spleen size is significantly influenced by body height and sex: establishment of normal values for spleen size at US with a cohort of 1200 healthy individuals. Radiology. 2016;279:306–13. Maggio M, De Vita F, Fisichella A, Lauretani F, Ticinesi A, Ceresini G, et al. The role of the multiple hormonal dysregulation in the Onset of Anemia of Aging: Focus on Testosterone, IGF-1, and thyroid hormones. Int J Endocrinol. 2015;2015:1–22. Mitchell E, Graham AL, Úbeda F, Wild G. On maternity and the stronger immune response in women. Nat Commun. 2022;1.